TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity,
leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of
immunosuppressive adenosine, which may change the tumor microenvironment and promote
anti-tumor immune response.
This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of
TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and
standard chemotherapies.
Phase:
Phase 1
Details
Lead Sponsor:
Tizona Therapeutics, Inc Trishula Therapeutics, Inc.